

November 16, 2019

Listing Department
BSE LIMITED

P J Towers, Dalal Street, Fort,
Mumbai-400 001

Code: 532 321

Listing Department

NATIONAL STOCK EXCHANGE OF INDIA LIMITED

Exchange Plaza, Bandra Kurla Complex,
Bandra (E),
Mumbai-400 051

Code: CADILAHC

Re.: Press Release

Dear Sir/Madam,

Please find enclosed a copy of press release dated November 16, 2019 titled "Zydus receives tentative approval from the USFDA for Apremilast Tablets."


The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Thanking you,

Yours faithfully,

For, **CADILA HEALTHCARE LIMITED**



DHAVAL N. SONI
COMPANY SECRETARY



Encl.: As above

Zydus receives tentative approval from the USFDA for Apremilast Tablets

Ahmedabad, 16 November, 2019

Zydus Cadila has received the tentative approval from the USFDA to market Apremilast Tablets (US RLD- Otezla®) 10 mg, 20 mg, and 30 mg. This medication is used to treat a certain type of arthritis (psoriatic arthritis) and a certain type of skin condition (moderate to severe plaque psoriasis). It is also used to treat mouth sores in people who have Behcet's disease, a type of inflammatory disorder and helps to reduce the pain and improve the healing of these mouth sores. It will be manufactured at the group's manufacturing facility at SEZ, Ahmedabad.

The group now has 276 approvals and has so far filed over 360 ANDAs since the commencement of the filing process in FY 2003-04.

About Zydus Cadila

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs over 24,000 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research-based pharmaceutical company by 2020.
